Amryt Pharma plc - American Depositary Shares (NQ:AMYT)

N/A UNCHANGED

Last Price Updated: 4:00 PM EDT, Apr 11, 2023 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Amryt Pharma plc - American Depositary Shares

< Previous 1 2 3 Next >

Amryt Reports Q3 2022 Financial and Operational Results

November 03, 2022

From Amryt Pharma plc

Via GlobeNewswire

Amryt Supports Acromegaly Awareness Day 2022

October 31, 2022

From Amryt Pharma plc

Via GlobeNewswire

The British Journal of Dermatology Publishes Results from Amryt’s EASE Phase 3 Trial in Epidermolysis Bullosa

October 25, 2022

From Amryt Pharma plc

Via GlobeNewswire

Amryt Supports Global EB Awareness Week 2022

October 24, 2022

From Amryt Pharma plc

Via GlobeNewswire

Filsuvez's European Approval Adds Growth Driver For Amryt Pharma ↗

June 24, 2022

Via Benzinga

Recap: Amryt Pharma Q1 Earnings ↗

May 04, 2022

Amryt Pharma (NASDAQ:AMYT) reported its Q1 earnings results on Wednesday, May 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Amryt Shares Trading Higher As EMA Endorses Approval Of Filsuvez In Genetic Skin Disease ↗

April 22, 2022

Via Benzinga

Amryt to Report Q3 2022 Results on November 3, 2022

October 19, 2022

From Amryt Pharma plc

Via GlobeNewswire

COMP adopts positive opinion on Orphan Disease Designation for Mycapssa® for the treatment of Acromegaly

October 18, 2022

From Amryt Pharma plc

Via GlobeNewswire

Amryt Receives Reimbursement Approval from the Dutch Ministry of Health for Myalepta® (metreleptin)

October 17, 2022

From Amryt Pharma plc

Via GlobeNewswire

Important Biotech Catalysts For September 8, 2022 - End Of The Day Summary ↗

September 08, 2022

Via Benzinga

Amryt Posts Long-Term Safety, Efficacy Mycapssa Data In Acromegaly Patients ↗

April 13, 2022

Amryt Pharma Plc (NASDAQ: AMYT) has

Via Benzinga

Recap: Amryt Pharma Q4 Earnings ↗

March 09, 2022

Amryt Pharma (NASDAQ:AMYT) reported its Q4 earnings results on Wednesday, March 9, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings...

Via Benzinga

Amryt Secures UK Regulatory Nod And Orphan Disease Status For Skin Disorder Candidate ↗

September 08, 2022

The Medical Healthcare & Products Regulatory Agency (MHRA) has granted Marketing Authorisation Approval (MAA) and Orphan Disease Designation (ODD) for Amryt’s (NASDAQ: AMYT) lead candidate Filsuvez for...

Via Benzinga

The Daily Biotech Pulse: Much Awaited FDA Nod For Novavax's COVID-19 Shot, DSMB Suggests ContraFect To Stop Antimicrobial-Resistant Infection Study, CytomX Restructures ↗

July 14, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

July 14, 2022

Via Benzinga

Amryt Shares Shoot Higher As FDA Grants Orphan Drug Status To Carcinoid Tumor Candidate ↗

July 14, 2022

The US Food and Drug Administration (FDA) has granted Orphan Drug Designation to Amryt’s (NASDAQ: AMYT) lead drug Mycapssa for the treatment of carcinoid syndrome. Carcinoid syndrome (CS) is the most...

Via Benzinga

The Daily Biotech Pulse: F-Star Therapeutics Buyout, Orphan Drug Tag For VBI's Brain Cancer Vaccine, Xenon's Epilepsy Candidate Shows Promise ↗

June 23, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

June 23, 2022

Via Benzinga

Amryt Pharma Plc (NASDAQ:AMYT) Shareholder Notice: Investigation Concerning Possible Wrongdoing ↗

May 04, 2022

San Diego, CA -- (SBWIRE) -- 05/04/2022 -- An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Amryt Pharma plc.

Via SBWire

Amryt Pharma Plc (NASDAQ:AMYT) Investor Notice: Investigation over Possible Violations of Securities Laws ↗

March 21, 2022

San Diego, CA -- (SBWIRE) -- 03/21/2022 -- Amryt Pharma plc is under investigation over potential securities laws violations in connection with certain financial statements.

Via SBWire

Amryt Pharma's Q4 FY21 Sales, FY22 Guidance Shy Of Street Consensus ↗

March 09, 2022

Amryt Pharma Plc's (NASDAQ: AMYT) Q4 FY21 sales increased 29% Y/Y to $54.8 million, missing the consensus of $56.81 million. The growth was driven by metreleptin...

Via Benzinga

55 Biggest Movers From Friday ↗

April 25, 2022

Gainers Vallon Pharmaceuticals, Inc. (NASDAQ: VLON) shares jumped 100.9% to close at $2.27 on Friday. Vallon Pharmaceuticals engaged Ladenburg Thalmann & Co Inc to evaluate...

Via Benzinga

The Daily Biotech Pulse: Pfizer Begins Late-Stage Pediatric COVID Pill Study, Midatech And J&J Unit Expand R&D Collaboration, AbbVie-Alvotech Settle Humira Dispute ↗

March 09, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus AbbVie Settles With Alvotech On Humira Biosimilar Patent Dispute AbbVie, Inc...

Via Benzinga

Earnings Scheduled For March 9, 2022 ↗

March 09, 2022

Companies Reporting Before The Bell • REV Group (NYSE:REVG) is expected to report quarterly earnings at $0.11 per share on revenue of $529.44 million. • Express (...

Via Benzinga

A Preview Of Amryt Pharma's Earnings ↗

March 08, 2022

Amryt Pharma (NASDAQ:AMYT) is set to give its latest quarterly earnings report on Wednesday, 2022-03-09. Here's what investors need to know before the announcement. Analysts...

Via Benzinga

The Week Ahead In Biotech (March 6-12): Quiet Week On Tap With Earnings Season Reaching It Final Leg ↗

March 06, 2022

Biotech stocks reversed course in the week ending March 4, as the Ukrainian crisis weighed down on the broader market as well as the sector. The iShares Biotechnology ETF (...

Via Benzinga

FDA Rejects Amryt Pharma's Oleogel-S10 Application For Skin Blistering Disorder ↗

February 28, 2022

Amryt Pharma Plc (NASDAQ: AMYT) has received a Complete Response Letter (CRL) from the FDA regarding Oleogel-S10 application for cutaneous manifestations of...

Via Benzinga

67 Biggest Movers From Yesterday ↗

March 01, 2022

Gainers Mullen Automotive, Inc. (NASDAQ: MULN) climbed 145.6% to close at $1.69 on Monday after the company reported progress on solid-state polymer battery pack...

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

February 28, 2022

Gainers IntriCon (NASDAQ:IIN) shares increased by 37.4% to $23.93 during Monday's regular session. The current volume of 1.0 million shares is 3684.0% of IntriCon'...

Via Benzinga

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.